{"entity":{"id":"nct04641247","kind":"trial","name":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study","aka":[],"tldr":"A phase 2 trial of Niraparib in ovarian cancer, run by GlaxoSmithKline, now recruiting.","summary":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study is a phase 2 interventional study registered as NCT04641247 by GlaxoSmithKline, with 37 participants planned, started 2021-04-16 and due to reach its primary completion in 2026-12-28. Interventions recorded: Niraparib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04641247","url":"https://clinicaltrials.gov/study/NCT04641247"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["niraparib"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04641247","phase":"2","setting":"An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib","sponsor":"GlaxoSmithKline","enrolled":37,"outcomes":[]},"route":"/trials/nct04641247/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}